Human medicines European public assessment report (EPAR): Doxolipad, doxorubicin, Breast Neoplasms,Ovarian Neoplasms, Date of refusal: 08/08/2019, Status: Refused

Human medicines European public assessment report (EPAR): Mvasi, bevacizumab, Carcinoma, Renal Cell,Peritoneal Neoplasms,Ovarian Neoplasms,Breast Neoplasms,Carcinoma, Non-Small-Cell Lung,Fallopian Tube Neoplasms, Date of authorisation: 14/01/2018, Revision: 3, Status: Authorised

Case Medical Research ◽

10.31525/cmr-4e9a82 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Ovarian Neoplasms ◽

Small Cell ◽

Small Cell Lung ◽

Assessment Report ◽

Peritoneal Neoplasms ◽

European Public ◽

European Public Assessment Report ◽

Fallopian Tube Neoplasms ◽

Carcinoma Renal Cell

Download Full-text

Human medicines European public assessment report (EPAR): Mvasi, bevacizumab, Carcinoma, Renal Cell,Peritoneal Neoplasms,Ovarian Neoplasms,Breast Neoplasms,Carcinoma, Non-Small-Cell Lung,Fallopian Tube Neoplasms, Date of authorisation: 14/01/2018, Revision: 4, Status: Authorised

Case Medical Research ◽

10.31525/cmr-58719b ◽

2019 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Ovarian Neoplasms ◽

Small Cell ◽

Small Cell Lung ◽

Assessment Report ◽

Peritoneal Neoplasms ◽

European Public ◽

European Public Assessment Report ◽

Fallopian Tube Neoplasms ◽

Carcinoma Renal Cell

Download Full-text

Human medicines European public assessment report (EPAR): Avastin, bevacizumab, Carcinoma, Non-Small-Cell Lung,Breast Neoplasms,Ovarian Neoplasms,Colorectal Neoplasms,Carcinoma, Renal Cell, Date of authorisation: 12/01/2005, Revision: 51, Status: Authorised

Case Medical Research ◽

10.31525/cmr-1b3e44e ◽

2019 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Colorectal Neoplasms ◽

Renal Cell ◽

Ovarian Neoplasms ◽

Small Cell ◽

Small Cell Lung ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Carcinoma Renal Cell

Download Full-text

Human medicines European public assessment report (EPAR): Caelyx, doxorubicin, Sarcoma, Kaposi,Multiple Myeloma,Ovarian Neoplasms,Breast Neoplasms, Date of authorisation: 20/06/1996, Revision: 30, Status: Authorised

Case Medical Research ◽

10.31525/cmr-5871c9 ◽

2019 ◽

Author(s):

Keyword(s):

Multiple Myeloma ◽

Breast Neoplasms ◽

Ovarian Neoplasms ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Caelyx, doxorubicin, Sarcoma, Kaposi,Multiple Myeloma,Ovarian Neoplasms,Breast Neoplasms, Date of authorisation: 20/06/1996, Revision: 29, Status: Authorised

Case Medical Research ◽

10.31525/cmr-399684 ◽

2018 ◽

Author(s):

Keyword(s):

Multiple Myeloma ◽

Breast Neoplasms ◽

Ovarian Neoplasms ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Ecansya (previously Capecitabine Krka), capecitabine, Colonic Neoplasms,Breast Neoplasms,Colorectal Neoplasms,Stomach Neoplasms, Date of authorisation: 19/04/2012, Revision: 9, Status: Authorised

Case Medical Research ◽

10.31525/cmr-3996c4 ◽

2018 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Colorectal Neoplasms ◽

Stomach Neoplasms ◽

Colonic Neoplasms ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Halaven, eribulin, Breast Neoplasms,Liposarcoma, Date of authorisation: 17/03/2011, Revision: 20, Status: Authorised

Case Medical Research ◽

10.31525/cmr-3996b1 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Talzenna, talazoparib, Breast Neoplasms, Date of authorisation: 20/06/2019, Status: Authorised

Case Medical Research ◽

10.31525/cmr-172b113 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Herzuma, trastuzumab, Stomach Neoplasms,Breast Neoplasms, Date of authorisation: 08/02/2018, Revision: 4, Status: Authorised

Case Medical Research ◽

10.31525/cmr-39966a ◽

2019 ◽

Author(s):

Keyword(s):

Breast Neoplasms ◽

Stomach Neoplasms ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Yondelis, trabectedin, Ovarian Neoplasms,Sarcoma, Date of authorisation: 17/09/2007, Revision: 24, Status: Authorised

Case Medical Research ◽

10.31525/cmr-2935cd6 ◽

2020 ◽

Author(s):

Keyword(s):

Ovarian Neoplasms ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text